# CAMBRIA-1 (NCT05774951)

> A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05774951
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Breast Cancer, Early Breast Cancer
- Interventions: Camizestrant; Tamoxifen; Anastrozole; Letrozole; Exemestane
- Enrollment: 4300
- Primary outcome: Invasive breast cancer-free survival (IBCFS)

## Commentary we found

- YouTube: 26
- Podcasts: 16
- X threads: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cambria-1-nct05774951

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05774951", "email": "<work email>"}; the inbox owner confirms by the emailed link.